AU2008229264A1 - Method for treating CB2 receptor mediated pain - Google Patents

Method for treating CB2 receptor mediated pain Download PDF

Info

Publication number
AU2008229264A1
AU2008229264A1 AU2008229264A AU2008229264A AU2008229264A1 AU 2008229264 A1 AU2008229264 A1 AU 2008229264A1 AU 2008229264 A AU2008229264 A AU 2008229264A AU 2008229264 A AU2008229264 A AU 2008229264A AU 2008229264 A1 AU2008229264 A1 AU 2008229264A1
Authority
AU
Australia
Prior art keywords
halogen
optionally substituted
alkyl
hydroxy
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008229264A
Other languages
English (en)
Inventor
Christopher M. Flores
Mark J. Macielag
Kevin Paul Pavlick
Mingde Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008229264(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2008229264A1 publication Critical patent/AU2008229264A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008229264A 2007-03-21 2008-02-27 Method for treating CB2 receptor mediated pain Abandoned AU2008229264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89601407P 2007-03-21 2007-03-21
US60/896,014 2007-03-21
PCT/US2008/055084 WO2008115671A1 (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain

Publications (1)

Publication Number Publication Date
AU2008229264A1 true AU2008229264A1 (en) 2008-09-25

Family

ID=39766329

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008229264A Abandoned AU2008229264A1 (en) 2007-03-21 2008-02-27 Method for treating CB2 receptor mediated pain

Country Status (14)

Country Link
US (1) US20080234347A1 (https=)
EP (1) EP2139326A4 (https=)
JP (1) JP2010522181A (https=)
KR (1) KR20090120499A (https=)
CN (1) CN101677556A (https=)
AR (1) AR065800A1 (https=)
AU (1) AU2008229264A1 (https=)
CA (1) CA2681381A1 (https=)
CL (1) CL2008000827A1 (https=)
MX (1) MX2009010162A (https=)
PE (1) PE20090062A1 (https=)
TW (1) TW200901972A (https=)
UY (1) UY30973A1 (https=)
WO (1) WO2008115671A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101787116B1 (ko) * 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
EP3541371A4 (en) * 2017-11-15 2020-07-22 Panag Pharma Inc. METHODS OF TREATING INTERSTITIAL CYSTITIS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
PL1937259T3 (pl) * 2005-09-23 2012-04-30 Janssen Pharmaceutica Nv Heksahydrocykloheptapirazolowe modulatory receptora kanabinoidowego

Also Published As

Publication number Publication date
TW200901972A (en) 2009-01-16
CA2681381A1 (en) 2008-09-25
US20080234347A1 (en) 2008-09-25
MX2009010162A (es) 2009-10-12
CN101677556A (zh) 2010-03-24
JP2010522181A (ja) 2010-07-01
PE20090062A1 (es) 2009-01-26
EP2139326A4 (en) 2011-06-15
WO2008115671A1 (en) 2008-09-25
CL2008000827A1 (es) 2008-09-26
UY30973A1 (es) 2008-09-30
EP2139326A1 (en) 2010-01-06
KR20090120499A (ko) 2009-11-24
AR065800A1 (es) 2009-07-01

Similar Documents

Publication Publication Date Title
TWI585083B (zh) 用於預防及／或治療手術後疼痛的σ配子
CN103313709B (zh) σ配体在骨癌疼痛中的用途
JPS63215627A (ja) 新規な治療用医薬組成物
CN105873580B (zh) 加巴喷丁类化合物与σ受体配体的组合物
CN103080103A (zh) 作为单酰甘油脂肪酶抑制剂的氧代哌嗪-氮杂环丁烷酰胺和氧代二氮杂*-氮杂环丁烷酰胺
US9931346B2 (en) Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations
AU2014255837A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
CN101321523A (zh) Cb1拮抗剂在治疗精神分裂症的阴性症状中的用途
PT1931335E (pt) Moduladores canabinóides de hexa-hidrociclooctil-pirazole
AU2008229265A1 (en) Method for treating CB2 receptor mediated pain
AU2008229264A1 (en) Method for treating CB2 receptor mediated pain
TW200901976A (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
US20090215850A1 (en) Method for treating cb2 receptor mediated pain
WO2007095513A1 (en) Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
CN101312952B (zh) 四氢-环戊二烯并吡唑大麻素调节剂
BRPI0709994A2 (pt) combinação de compostos orgánicos
ES2375213T3 (es) Moduladores de cannabinoides de hexadhidro-cicloheptapirazol.
JP2008512415A (ja) 中枢神経障害性疼痛の治療のためのアリール（またはヘテロアリール）アゾリルカルビノールの誘導体
EP3423444A1 (en) Novel types of c-3 substituted kinurenic acid derivatives with improved neuroprotective activity
CN106456641A (zh) 眼后段疾病的预防或治疗剂

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application